SecBot SecBot
SECBOTREPLAY Home › Report › SEPN

SEPN · Septerna announced the initiation of Phase 1 clinical trials for its…

Septerna, Inc. · 8-K filed Apr 13, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 13, 2026 at 08:30 ET

Septerna announced the initiation of Phase 1 clinical trials for its oral PTH1R agonist SEP-479 for hypoparathyroidism, with data expected in late 2026 or early 2027. The company also provided updates on its other clinical programs including SEP-631 and its collaboration with Novo Nordisk, while highlighting its cash runway into 2029.

  • Company initiated Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism
  • Phase 1 trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers
  • Data from the trial is anticipated in late 2026 or early 2027
  • SEP-631 Phase 1 study demonstrated robust pharmacodynamics with QD dosing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access